Possible Involvement of Advanced Glycation End-Products (AGEs) in the Pathogenesis of Alzheimer's Disease

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|10|973-978

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.10, 2008-04, pp. : 973-978

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 969-972

Bentham Science Publishers

Access to resources Recommend Favorite

Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimer's Disease

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 4, Iss. 3, 2005-06 ,pp. : 249-266

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [ Advanced Glycation End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi ]

By  

Current Pharmaceutical Design, Vol. 14, Iss. 10, 2008-04 ,pp. : 939-939

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs), Oxidative Stress and Diabetic Retinopathy

By  

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 3, 2011-03 ,pp. : 362-368

Bentham Science Publishers

Access to resources Recommend Favorite

Advanced Glycation End Products (AGEs) and their Receptor (RAGE) System in Diabetic Retinopathy

By  

Current Drug Discovery Technologies, Vol. 3, Iss. 1, 2006-03 ,pp. : 83-88

Bentham Science Publishers

Access to resources Recommend Favorite